NCT04803318View on ClinicalTrials.gov

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2037

Conditions
Solid Tumor, AdultHepatocellular Carcinoma
Interventions
DRUG

Combination of three inhibitors Trametinib, Everolimus and Lenvatinib

Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.

Trial Locations (1)

510260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER